GlassScriptPhysician profile
Barry A Robertson
NPI 1629069612
$852.23
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $271 · 2021: $175 · 2022: $136 · 2023: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $273.91 | 2021-2023 | Vraylar, Viberzi, Linzess |
| Biogen, INC. | $137.00 | 2020 | |
| Pulmonx Corporation | $119.92 | 2020 | |
| Astellas Pharma US INC | $103.20 | 2019-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $54.10 | 2022 | |
| Novo Nordisk INC | $26.31 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.93 | 2019 | |
| Almatica Pharma LLC | $19.97 | 2022 | |
| Amgen INC. | $19.17 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.81 | 2019 | |
| Merck Sharp & Dohme LLC | $16.27 | 2023 | Verquvo, Steglatro, Belsomra |
| Avanir Pharmaceuticals, INC. | $14.99 | 2022 | |
| Allergan, INC. | $13.98 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.